Risk for Osteoporosis and Antiresorptive Therapies in Patients with Crohn's Disease

Abstract

Background:

The risk of osteoporosis is greater in patients with inflammatory bowel disease (IBD) because of several related risk factors such as the prolonged use of corticosteroids, the malabsorption of calcium and vitamin D following small-bowel disease or small-bowel resections, and the inflammatory process resulting from the illness. A reduction in bone mineral density (BMD) has been reported in 30–75% of patients with IBD (Crohn's disease or ulcerative colitis). An evaluation of the risk factors of osteoporosis should be performed to identify those in need of antiresorptive drug therapies (ART) and/or calcium and vitamin D supplements.

Objective:

To determine whether patients with Crohn's disease at risk for osteoporosis or already having decreased BMD were identified as such and treated with appropriate therapy.

Methods:

A cross-sectional study was performed among 54 white patients with Crohn's disease who attended a gastroenterology specialized clinic between January and March 2002. All patients with Crohn's disease having an outpatient medical visit were asked to participate in the study. Patients who agreed to the study were questioned for Crohn's disease activity index (CDAI) and osteoporosis risk factors such as nutrition, lifestyle, and corticosteroid therapy. Serum bone-specific markers and nutritional status were assessed. BMD test of the lumbar vertebrae (L2–L4) and the nondominant hip were assessed with dual-energy X-ray absorptiometry if the participants did not have a BMD test in the year prior to the study. ART and calcium/vitamin D use were assessed through a questionnaire and on community pharmaceutical drug services in the 2 year period prior to the evaluation.

Results:

Mean age and CDAI severity score were 41.5 years and 145, respectively. None of the patients was evaluated for BMD in the year prior to the study. Osteopenia at the nondominant hip and/or lumbar vertebrae was seen in 29 patients. Eighty-two percent of patients with a T score under −2 SD had not been exposed to ART; 84% of patients with more than 4 risk factors for osteoporosis and a T score less than −1.5 SD had not received ART. Moreover, 88% of patients with a T score less than −1.5 SD and receiving corticosteroid therapy had not been treated with ART.

Conclusions:

The presence of osteoporosis risk factors and osteopenia had not been recognized and treated in our population. Adequate osteoporosis management should be implemented in patients with Crohn's disease to reduce the occurrence of osteoporotic fractures.

Get full access to this article

View all access options for this article.

References

Pollak

Karmeli

Eliakim

Ackerman

Tabb

Rachmilewitz

. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483–90.

Valentine

Sninsky

. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94: 878–83.

Haugeberg

Vetvik

Stallemo

Bitter

Mikkelsen

Stokkeland

. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: Cross-sectional data from a population-based study. Scand J Gastroenterol 2001; 36: 759–65.

American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 791–4.

Schoon

Blok

Geerling

Russel

Stockbrugger

Brummer

. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119: 1203–8.

Andreassen

Rungby

Dahlerup

Mosekilde

. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32: 1247–55.

Society of Obstetricians and Gynaecologists of Canada. Canadian Menopause Consensus Conference. J Soc Obstet Gynaecol Can 1998; 20: 1243–72.

Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Introduction. Osteoporos Int 1998; 8 (suppl 4): S7–80.

Scott

Gaywood

Scott

, for the British Society of Gastroenterology. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 2000; 46 (suppl 1): i1–8.

10.

WHO Study Group on Assessment of Fracture Risk and Its Application to Screening for PostMenopausal Osteoporosis. Assessment of fracture risk and its application to screening for post menopausal osteoporosis: report of a WHO study group (WHO technical series 843). Geneva: WHO, 1994. www.who.int (accussed 2005 Dec 20).

11.

Bischoff

Herrmann

Goke

Manns

von zur Muhlen

Brabant

. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157–63.

12.

Best

Becktel

Singleton

Kern

Jr.

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44.

13.

Stein

Lichtenstein

. Medical therapy for Crohn's disease: The state of the art. Surg Clin North Am 2001; 81: 71–101, viii.

14.

Kenny

Prestwood

. Osteoporosis, pathogenesis, diagnosis, and treatment in older adults. Rheum Dis Clin North Am 2000; 26: 569–91.

15.

Brown

Josse

, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167 (10 suppl): S1–34.

16.

Sebaldt

Adachi

. Canadian Database of Osteoporosis and Osteopenia Patients (CANDOO). Canadian Organization for the Advancement of Computers in Healthcare proceedings. 1996; 21: 41–4, Ottawa, May 1996.

17.

Adachi

Olszynski

Hanley

, Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000; 29: 228–51.

18.

Strategic Action Working Group on Osteoporosis. Ontario Women's Health Council. Report of the Strategic Action Working Group on Osteoporosis. A framework and strategy for the prevention and management of osteoporosis 2000: 1–44. www.womenshealthcouncil.com (accessed 2005 Dec 20).

19.

Canada.

Health

Handbook for Canada's physical activity guide to healthy active living for older adults, Ottawa, ON, Canada. Catal. No H39–429/1999-2F.

20.

1997 Physical Activity Monitor. Ontario: Canadian Fitness and Lifestyle Research Institute, Bulletin no. 33.

21.

Scott

. A strategy for osteoporosis in gastroenterology. Eur J Gastroenterol Hepatol 1998; 10: 689–98.

22.

Jahnsen

Falch

Aadland

Mowinckel

. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study. Gut 1997; 40: 313–9.

23.

Bischoff

Herrmann

Goke

Manns

von zur Muhlen

Brabant

. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157–63.

24.

Bernstein

Blanchard

Leslie

Wajda

. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795–9.

25.

Ghosh

Cowen

Hannan

Ferguson

. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031–9.

26.

Card

West

Hubbard

Logan

. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: A population based cohort study. Gut 2004; 53: 251–5.

27.

Bernstein

Blanchard

Metge

Yogendran

. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003; 98: 1797–801.

28.

Haderslev

Tjellesen

Sorensen

Staun

. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639–46.

29.

Bartram

Peaston

Rawlings

Francis

Thompson

. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1121–7.